Table 2 a, b Median ± standard deviation of lymphocyte subpopulations (absolute count in 10³/ml) in different subgroups

n

T ly

CD4+

CD8+

B ly

NK cells

CD5+

all patients at first relapse

191

1.3 ± 0.4

0.8 ± 0.3

0.4 ± 0.2

0.2 ± 0.1

0.2 ± 0.1

1.3 ± 0.4

all patients at baseline (BL)^a

191

1.3 ± 0.4

0.8 ± 0.3

0.5 ± 0.2

0.2 ± 0.1

0.3 ± 0.2

1.3 ± 0.4

all patients at 48 months (48)^b

181

1.3 ± 0.5

0.8 ± 0.3

0.4 ± 0.2

0.3 ± 0.2

0.2 ± 0.1

1.3 ± 0.5

patients without relapse at BL

77

1.3 ± 0.3

0.8 ± 0.2

0.4 ± 0.2

0.2 ± 0.1

0.3 ± 0.2

1.3 ± 0.3

patients without relapse at 48^b

77

1.3 ± 0.4

0.8 ± 0.2

0.4 ± 0.2

0.3 ± 0.1

0.2 ± 0.1

1.4 ± 0.4

patients with relapse at BL

114

1.3 ± 0.5

0.8 ± 0.3

0.5 ± 0.2

0.2 ± 0.1

0.3 ± 0.1

1.3 ± 0.5

patients with relapse at 48^b

104

1.3 ± 0.5

0.8 ± 0.3

0.4 ± 0.2

0.2 ± 0.2

0.2 ± 0.1

1.3 ± 0.6

patients without CPD at BL

154

1.3 ± 0.4

0.8 ± 0.3

0.4 ± 0.2

1.3 ± 0.4

patients without CPD at 48^b

148

1.3 ± 0.5

0.8 ± 0.3

0.4 ± 0.2

0.3 ± 0.2

0.2 ± 0.1

1.4 ± 0.5

patients with CPD at BL

37

1.2 ± 0.4

0.3 ± 0.2

0.2 ± 0.1

0.2 ± 0.1

1.2 ± 0.4

patients with CPD at 48^b

33

1.1 ± 0.5

0.8 ± 0.3

0.3 ± 0.2

0.3 ± 0.2

0.1 ± 0.1

1.2 ± 0.6

n

DR+ CD3+

CD45RA+

CD45RA+ CD4+

all patients at first relapse

191

0.1 ± 0.1

1.1 ± 0.4

0.5 ± 0.2

all patients at baseline (BL)^a

191

0.2 ± 0.1

1.2 ± 0.4

0.5 ± 0.3

all patients at 48 months (48)^b

181

0.2 ± 0.1

1.1 ± 0.5

0.4 ± 0.2

patients without relapse at BL

77

0.2 ± 0.1

1.2 ± 0.3

0.5 ± 0.2

patients without relapse at 48^b

77

0.2 ± 0.1

1.1 ± 0.4

0.4 ± 0.2

patients with relapse at BL

114

0.2 ± 0.1

1.2 ± 0.5

0.5 ± 0.3

patients with relapse at 48^b

104

0.1 ± 0.1

1.1 ± 0.6

0.4 ± 0.2

patients without CDP at BL

154

0.2 ± 0.1

1.2 ± 0.4

0.5 ± 0.3

patients without CPD at 48^b

148

0.1 ± 0.1

1.1 ± 0.5

0.4 ± 0.2

patients with CPD at BL

37

0.1 ± 0.2

1 ± 0.4

0.4 ± 0.2

patients with CPD at 48^b

33

0.1 ± 0.1

1 ± 0.6

0.3 ± 0.2